DK2744515T3 - Kombinationsterapi med et anti-cd19-antistof og en nitrogensennep - Google Patents
Kombinationsterapi med et anti-cd19-antistof og en nitrogensennep Download PDFInfo
- Publication number
- DK2744515T3 DK2744515T3 DK12747923.6T DK12747923T DK2744515T3 DK 2744515 T3 DK2744515 T3 DK 2744515T3 DK 12747923 T DK12747923 T DK 12747923T DK 2744515 T3 DK2744515 T3 DK 2744515T3
- Authority
- DK
- Denmark
- Prior art keywords
- antibody
- combination therapy
- nitrogen mustard
- mustard
- nitrogen
- Prior art date
Links
- 238000002648 combination therapy Methods 0.000 title 1
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical class ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 title 1
- 229960004961 mechlorethamine Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161523861P | 2011-08-16 | 2011-08-16 | |
| EP11177658 | 2011-08-16 | ||
| US201261647539P | 2012-05-16 | 2012-05-16 | |
| US201261654097P | 2012-06-01 | 2012-06-01 | |
| PCT/EP2012/065906 WO2013024097A1 (en) | 2011-08-16 | 2012-08-14 | Combination therapy with an anti - cd19 antibody and a nitrogen mustard |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2744515T3 true DK2744515T3 (da) | 2022-03-28 |
Family
ID=47714801
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK12747923.6T DK2744515T3 (da) | 2011-08-16 | 2012-08-14 | Kombinationsterapi med et anti-cd19-antistof og en nitrogensennep |
Country Status (24)
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2951427A1 (en) * | 2014-06-16 | 2015-12-23 | Xencor, Inc. | Treatment for chronic lymphocytic leukemia (cll) |
| CA2986175A1 (en) * | 2015-05-26 | 2016-12-01 | Morphosys Ag | Combination of an anti-cd19 antibody and a bruton's tyrosine kinase inhibitor and uses thereof |
| AU2016311136B2 (en) | 2015-08-21 | 2022-02-17 | Incyte Corporation | Combinations and uses thereof |
| EP3436070A4 (en) | 2016-03-29 | 2019-11-27 | University of Southern California | AGAINST CANCER, CHIMERIC ANTIGEN RECEPTORS |
| MA45124B1 (fr) * | 2016-05-30 | 2021-05-31 | Morphosys Ag | Procédés permettant de prédire un bénéfice thérapeutique d'une thérapie anti-cd19 chez des patients |
| IL266216B2 (en) * | 2016-10-28 | 2023-09-01 | Morphosys Ag | Combination of anti-cd19 antibody with bcl-2 inhibitor and uses thereof |
| IL266892B2 (en) | 2016-12-02 | 2025-10-01 | Univ Southern California | Artificial immune receptors and methods of using them |
| PL3630177T3 (pl) * | 2017-05-31 | 2024-04-08 | Morphosys Ag | Paradygmat leczenia dla leczenia skojarzonego przeciwciałem anty-cd19 i wenetoklaksem |
| KR20200030337A (ko) | 2018-09-12 | 2020-03-20 | 주식회사 녹십자랩셀 | 종양 치료를 위한 항-cd 19 항체 및 자연살해세포를 포함하는 약학적 조합물 |
| KR20240131370A (ko) * | 2021-12-22 | 2024-08-30 | 인사이트 코포레이션 | 항-cd19 항체 요법을 위한 치료 패러다임 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1247080A (en) | 1983-03-08 | 1988-12-20 | Commonwealth Serum Laboratories Commission | Antigenically active amino acid sequences |
| US5686072A (en) | 1992-06-17 | 1997-11-11 | Board Of Regents, The University Of Texas | Epitope-specific monoclonal antibodies and immunotoxins and uses thereof |
| DE69909459T2 (de) * | 1998-04-21 | 2004-05-27 | Micromet Ag | Cd19xcd3 spezifische polypeptide und deren verwendung |
| CN100358577C (zh) * | 1999-05-07 | 2008-01-02 | 杰南技术公司 | 抗体在制备治疗哺乳动物自身免疫病的试剂中的用途 |
| MXPA03002262A (es) | 2000-09-18 | 2003-10-15 | Idec Pharma Corp | Terapia de combinacion para tratamiento de enfermedades autoinmunes usando una combinacion de anticuerpos inmunorreguladores/supresores de celulas b. |
| WO2003048731A2 (en) | 2001-12-03 | 2003-06-12 | Abgenix, Inc. | Antibody categorization based on binding characteristics |
| US20080260731A1 (en) * | 2002-03-01 | 2008-10-23 | Bernett Matthew J | Optimized antibodies that target cd19 |
| EP1648512A4 (en) | 2003-07-31 | 2009-01-21 | Immunomedics Inc | ANTI-CD19 ANTIBODIES |
| US7902338B2 (en) | 2003-07-31 | 2011-03-08 | Immunomedics, Inc. | Anti-CD19 antibodies |
| AR054094A1 (es) | 2004-11-05 | 2007-06-06 | Cephalon Inc | Tratamientos de cancer |
| MX2007015944A (es) | 2005-06-20 | 2008-03-07 | Medarex Inc | Anticuerpos cd19 y sus usos. |
| AU2006332155B2 (en) * | 2005-12-30 | 2013-01-10 | Cancer Research Technology Limited | Anti-CD19 antibodies with reduced immunogenicity |
| AU2007285976B2 (en) * | 2006-08-14 | 2011-08-18 | Xencor, Inc | Optimized antibodies that target CD19 |
| CA2662340C (en) | 2006-09-08 | 2016-08-02 | Medimmune, Llc | Humanized anti-cd19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease |
| DK2176298T3 (en) | 2007-05-30 | 2018-02-12 | Xencor Inc | Methods and compositions for inhibiting CD32B-expressing cells |
| DK2211904T3 (en) | 2007-10-19 | 2016-10-24 | Seattle Genetics Inc | Cd19-binding agents and uses thereof |
| EP2405937A4 (en) * | 2009-01-16 | 2012-06-20 | Glaxosmithkline Llc | CANCER THERAPY USING A COMBINATION OF BENDAMUSTIN AND AN ANTIBODY AGAINST CD20 |
| BRPI1005984A2 (pt) | 2009-02-23 | 2016-10-04 | Glenmark Pharmaceuticals Sa | anticorpo humanizado ou fragmento do mesmo que se liga ao cd19 humano, acido nucleico isolado, vetor, célula hospedeira, método para produzir um anticorpo humanizado ou fragmento do mesmo que se liga à cd12 humano, composição, imunoconjugado, uso de um anticorpo humanizado ou fragmento do mesmo, artigo de manufatura e kit |
| CA2765080C (en) | 2009-06-24 | 2018-07-17 | The Feinstein Institute For Medical Research | Methods for treating chronic lymphocytic leukemia |
| RU2012109451A (ru) * | 2009-08-14 | 2013-09-27 | Роше Гликарт Аг | Комбинированная терапия на основе афукозилированного антитела к cd20 в сочетании с флударабином и/или митоксантроном |
| TWI409079B (zh) * | 2009-08-14 | 2013-09-21 | Roche Glycart Ag | 非典型岩藻醣化ｃｄ２０抗體與苯達莫斯汀（ｂｅｎｄａｍｕｓｔｉｎｅ）之組合療法 |
| EP2501237A1 (en) * | 2009-11-06 | 2012-09-26 | Infinity Pharmaceuticals, Inc. | Oral formulations of a hedgehog pathway inhibitor |
-
2012
- 2012-08-14 SI SI201231989T patent/SI2744515T1/sl unknown
- 2012-08-14 PL PL12747923T patent/PL2744515T3/pl unknown
- 2012-08-14 MX MX2013014933A patent/MX354479B/es active IP Right Grant
- 2012-08-14 US US14/126,928 patent/US20140255427A1/en not_active Abandoned
- 2012-08-14 EP EP22155572.5A patent/EP4062936A1/en active Pending
- 2012-08-14 CN CN201280036571.XA patent/CN103732252B/zh active Active
- 2012-08-14 RU RU2014103492A patent/RU2625222C2/ru active
- 2012-08-14 KR KR1020207014299A patent/KR20200058583A/ko not_active Withdrawn
- 2012-08-14 PT PT127479236T patent/PT2744515T/pt unknown
- 2012-08-14 BR BR112013033919-5A patent/BR112013033919B1/pt active IP Right Grant
- 2012-08-14 SG SG10201606785UA patent/SG10201606785UA/en unknown
- 2012-08-14 KR KR1020197026462A patent/KR102115203B1/ko active Active
- 2012-08-14 EP EP12747923.6A patent/EP2744515B1/en active Active
- 2012-08-14 CA CA2841875A patent/CA2841875C/en active Active
- 2012-08-14 CA CA3137321A patent/CA3137321A1/en active Pending
- 2012-08-14 DK DK12747923.6T patent/DK2744515T3/da active
- 2012-08-14 HR HRP20220228TT patent/HRP20220228T1/hr unknown
- 2012-08-14 WO PCT/EP2012/065906 patent/WO2013024097A1/en not_active Ceased
- 2012-08-14 RS RS20220412A patent/RS63238B1/sr unknown
- 2012-08-14 HU HUE12747923A patent/HUE058350T2/hu unknown
- 2012-08-14 AU AU2012296907A patent/AU2012296907B2/en active Active
- 2012-08-14 KR KR1020147006936A patent/KR20140064873A/ko not_active Ceased
- 2012-08-14 JP JP2014525434A patent/JP6184952B2/ja active Active
- 2012-08-14 SM SM20220159T patent/SMT202200159T1/it unknown
- 2012-08-14 LT LTEPPCT/EP2012/065906T patent/LT2744515T/lt unknown
- 2012-08-14 ES ES12747923T patent/ES2909722T3/es active Active
-
2014
- 2014-01-02 IL IL230293A patent/IL230293B/en active IP Right Grant
-
2020
- 2020-04-03 US US16/839,777 patent/US20200353077A1/en not_active Abandoned
-
2022
- 2022-04-18 CY CY20221100289T patent/CY1125122T1/el unknown
-
2024
- 2024-01-12 US US18/411,350 patent/US20240366756A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2744515T3 (da) | Kombinationsterapi med et anti-cd19-antistof og en nitrogensennep | |
| CY2021036I2 (el) | Αντισωματα anti-angptl3 και χρησεις αυτων | |
| DK2785375T3 (da) | Anti-pd-l1-antistoffer og anvendelser deraf | |
| DK2744826T3 (da) | Kombinationsterapi med et anti-cd19-antistof og en purin-analog | |
| DK2668210T3 (da) | Anti-kit antistoffer og anvendelser deraf | |
| DK3502129T3 (da) | Konjugat omfattende oxyntomodulin og et immunoglobulinfragment og anvendelse deraf | |
| DK3556774T3 (da) | Anti-CD40-antistoffer og anvendelser deraf | |
| DK2914291T3 (da) | Anti-komplement-c1s-antistoffer og anvendelser deraf | |
| BR112014009050A2 (pt) | pirrolbenzodiazepinas e conjugados destas | |
| DK3197164T3 (da) | Afkodningsanordning og afkodningsfremgangsmåde | |
| DK2917790T3 (da) | Horologe med opbevaret og interchangeable face | |
| DK3381943T3 (da) | Anti-kit-antistoffer og anvendelser deraf | |
| DK2794654T3 (da) | Anti-phf-tau-antistoffer og deres anvendelser | |
| DK3597644T3 (da) | Kationiske aminlipider og anvendelser deraf | |
| IL231777A0 (en) | Antibodies against tl1a and uses thereof | |
| BR112014012137A2 (pt) | anticorpos anti-fgfr2 e suas utilizações | |
| DK2776469T3 (da) | Antistofmolekyler med specificitet for human ox40 | |
| DK3045187T3 (da) | Injektor og fremgangsmåde til samling | |
| BR112014002219A2 (pt) | conjugados anticorpo p97 e métodos de sua utilização | |
| DK3415157T3 (da) | N-acyldipeptidderivater og anvendelser deraf | |
| CO7071096A2 (es) | Anticuerpos anti-lgr5 e inmunoconjugados | |
| DK2839860T3 (da) | Pyrrolobenzodiazepiner og konjugater deraf | |
| DK2914633T3 (da) | Antistof/lægemiddel-konjugater og anvendelsesfremgangsmåder | |
| DK3339323T3 (da) | Anti-n3pglu-amyloid-beta-peptid-antistoffer og anvendelser deraf | |
| DK2950535T3 (da) | Fremgangsmåde og indretning til at afkode intra-forudsigelsestilstand |